Leachim

Travoprost, the active ingredient in Leachim, is a prostaglandin analog presented as an unknown/unknown for ocular use. It treats open-angle glaucoma and ocular hypertension in adult patients by lowering intra‑ocular pressure. GNH USA supplies Leachim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Travoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent development of glaucoma.

Travoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation or foreign‑body sensation. - Blurred vision: temporary visual disturbance after instillation. - Increased eyelash growth (hypertrichosis). - Darkening of the iris or peri‑ocular skin. - Eye pain or discomfort.

Serious or Rare Side Effects: - Uveitis or severe intra‑ocular inflammation. - Cystoid macular edema, especially in patients with risk factors. - Allergic reactions such as eyelid swelling or rash. - Vision loss due to uncontrolled pressure spikes. - Corneal epithelial defects. - Severe ocular infection.

Before prescribing Travoprost, clinicians should consider several safety aspects. - Monitor intra‑ocular pressure: ensure target pressure is achieved and maintained. - Assess for ocular infection or inflammation: avoid use in active conjunctivitis or keratitis. - Caution in patients with a history of herpetic eye disease: may trigger reactivation. - Avoid concurrent use with other prostaglandin analog eye drops: risk of excessive pressure reduction. - Evaluate for hypersensitivity to any component of the formulation. - Store at room temperature: keep in the original container, protect from moisture and light.

Travoprost can interact with other ophthalmic agents and systemic medications.

Major Interactions (Avoid): - Concurrent use of multiple intra‑ocular pressure‑lowering eye drops (e.g., other prostaglandin analogs) may cause excessive pressure reduction. - Co‑administration with ocular corticosteroids may diminish Travoprost efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops may have additive IOP‑lowering effects; monitor pressure closely. - Alpha‑agonist or carbonic anhydrase inhibitor eye drops may increase overall pressure‑lowering effect. - Systemic antihistamines or anticholinergics may exacerbate dry‑eye symptoms.